Avastin (bevacizumab) has been approved to treat patients with persistent, recurrent, or metastatic cervical cancer by the US Food and Drug Administration (FDA).
Avastin (bevacizumab) has been approved to treat patients with persistent, recurrent, or metastatic cervical cancer by the US Food and Drug Administration (FDA). The drug is a vascular endothelial growth factor-specific angiogenesis inhibitor with previous indications in metastatic colorectal cancer, advanced nonsquamous non-small cell lung cancer, metastatic kidney cancer, and glioblastoma.
News: New gene linked to breast cancer risk
This is the first drug to receive FDA approval for metastatic cervical cancer treatment since the 2006 approval of topotecan combined with cisplatin.
Due to the drug’s potential for significantly improved safety or effectiveness compared with standard therapies, Avastin received priority review and approval after less than 4 months of review.
Its safety and effectiveness were evaluated through a clinical study of 452 patients who had persistent, recurrent, or metastatic cervical cancer. Each participant was randomly assigned to receive either paclitaxel and topotecan with or without Avastin or paclitaxel and cisplatin with or without Avastin. Overall survival increased to 16.8 months in those who received chemotherapy plus Avastin, compared with 12.9 months in women who received chemotherapy alone.
Side effects associated with use Avastin in cervical cancer patients included decreased weight, decreased magnesium in the blood, hypertension, hyperglycemia, hypomagnesemia, headache, fatigue, decreased appetite, and urinary tract infection. Enterovaginal fistulas and gastrointestinal tract perforations were also seen in the participants treated with the drug.
Postmenopausal urinary incontinence treatment data found lacking
May 6th 2024Discover the findings of a comprehensive study exploring the efficacy of various treatments for postmenopausal urinary incontinence, shedding light on the current research gap and recommending avenues for future investigation.
Read More
Pioglitazone outperforms metformin in IVF for PCOS-related infertility
May 6th 2024A recent double-blind, randomized clinical trial revealed a higher clinical pregnancy rate with pioglitazone compared to metformin in polycystic ovarian syndrome patients undergoing in vitro fertilization, suggesting potential for improved outcomes.
Read More
Unlocking placenta accreta spectrum with single-cell gene targets
April 18th 2024Discover how cutting-edge single-cell RNA sequencing unveils molecular insights into placenta accreta spectrum disorders, potentially revolutionizing diagnostics and treatments for this life-threatening pregnancy complication.
Read More